Please login to the form below

Not currently logged in
Email:
Password:

serelaxin

This page shows the latest serelaxin news and features for those working in and with pharma, biotech and healthcare.

New drugs can't keep Novartis sales on the up

New drugs can't keep Novartis sales on the up

year. A decision to drop development of acute heart failure drug serelaxin (RLX030) also pegged back Novartis' profits, forcing the company to take a charge of $200m in the quarter.

Latest news

More from news
Approximately 11 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Other candidates in mid-stage testing include: natriuretic peptide receptor agonists from Capricor Therapeutics (cenderitide) and Palatin Technologies (PL-3994); Novartis' synthetic human relaxin 2 hormone serelaxin (knocked back by regulators

  • Interview: Elmar Schnee, Cardiorentis Interview: Elmar Schnee, Cardiorentis

    It's a company with great potential, according to Schnee, who has high hopes for its lead drug candidate ularitide – an investigational product that is in competition with Novartis' serelaxin to ... Because of the serelaxin trial [by Novartis], you saw

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics